Teprotumumab, an IGF-1R-blocking antibody, is the first targeted biologic therapy approved for TAO, demonstrating significant improvement in eyelid retraction, proptosis, and orbital inflammation, as shown in clinical studies [23,50]. The gene discussed is IGF1R; the disease is thromboangiitis obliterans.